Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

    NEXT STORY
    Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
    PREV STORY
    Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Surface Oncology to Present at the Baird 2019 Global Healthcare Conference

    author_avatar
    NASDAQ Market News

    CombiMatrix Forms Scientific Advisory Board; Includes Leaders in Reproductive Health, Pathology, Genetics, Molecular Biology and Health Policy

    IRVINE, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics ...

    author_avatar
    NASDAQ Market News

    Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer

    author_avatar
    NASDAQ Market News